Investors' Chronicle2 Helmi 2024

A guide to the FTSE 350: The Companies and Markets Show

Jennifer Johnson talks about the recently published GSK results, which showed strong growth, but the ongoing Zantac litigation is hanging over the shares. The team also touch on the prospects of rival pharma companies AstraZeneca and Indivior.

Our US-based journalist Arthur Sants joins from New York to unpack the growth, capex and future returns worries investors may have about the Magnificent Seven.

It’s then on to food producers AG Barr and Premier Foods with Mark Robinson, who shares news of trading updates, a new CEO sourced from an unlikely sector, and the prospects for growth.

Last on the agenda, Mark shares the thinking behind his latest feature on regulation and how investors can get involved with the companies using it to their advantage.

Dan Jones is joined by Jennifer Johnson, Alex Newman, Arthur Sants and Mark Robinson.

Timestamps

1:34 GSK and pharmaceutical firms

15:20 US Tech stocks

28:58 AG Barr and Premier Foods

36:22 Regulation

Mentioned in this episode

Semiconductor industry split between AI and the rest

GSK's RSV vaccine success makes its shares look cheap

Irn Bru maker AG Barr buoyed by new subsidiaries

Three companies benefitting from more regulation

FTSE 350 Review: The drinks brands likely to grow in a struggling market

FTSE 350 Review: Will GSK replace Astra as the investor favourite?

FTSE 350 Review: Software companies scramble to find AI uses

Investors' Chronicle has supported private investors in the UK for over 160 years by highlighting rewarding investment opportunities.

Investors' Chronicle is a service by the Financial Times.

Hosted on Acast. See acast.com/privacy for more information.

Tämä jakso on lisätty Podme-palveluun avoimen RSS-syötteen kautta eikä se ole Podmen omaa tuotantoa. Siksi jakso saattaa sisältää mainontaa.

Jaksot(1165)

AI inflation, defence stocks and India funds: Companies and Markets Show

This week begins with how booming demand for AI infrastructure is driving a sharp increase in the price of memory chips. Erin Withey is in the studio to explain what this means for supply chains, whic...

17 Heinä 28min

Labour’s social media plans, house prices and legal stocks: Companies and Markets Show

This week’s show begins with Labour’s decision to force tech giants to give more prominence to traditional news broadcasters on social media, to help battle misinformation. Valeria Martinez discusses ...

10 Heinä 26min

What is the gender health gap – and how to beat it

The gender health gap is an issue which affects far more than just wellbeing; it impacts your career, earnings and long-term financial stability.In this episode of Women and Wealth, funds editor Val C...

7 Heinä 24min

AI vs recruiters, another IPO and farming stocks

In this week’s episode, we turn to Britain’s recruitment stocks. Valeria Martinez looks at the impact of AI on hiring demand, which is hitting share prices, and also discusses the perennial question: ...

3 Heinä 35min

Ocado, asset managers and Telecom Plus: Companies and Markets Show

This week, we begin with online grocer Ocado (OCDO) following reports of a CEO switch. Julian Hofmann dives into what a potential change at the top will mean for the FTSE 250 company that has struggle...

26 Kesä 29min

AO World, wealth managers & Castings: Companies and Markets Show

This week, we begin proceedings with a look at the contrasting fortunes of two UK wealth managers: Aim-traded Tatton Asset Management (TAM) continues to reap rewards from its dominance of the model po...

19 Kesä 31min

Meeting with Fevara’s CEO: Lee and the IC

Fevara (FVA:127p) may be new in name, but its roots and expertise stretch back more than a century through the former Carr’s Group. In the wake of this major transformation, the livestock supplements ...

16 Kesä 44min

Investing in photonics, GSK and new opportunities in venture capital: Companies and Markets Show

This week’s show dives straight into safety and equipment maker Halma (HLMA), which reported its full-year results on Thursday morning. It may be time to re-evaluate the company’s description as one o...

12 Kesä 33min